Last $0.40 HKD
Change Today -0.005 / -1.23%
Volume 948.0K
455 On Other Exchanges
Symbol
Exchange
Hong Kong
As of 3:01 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

tianda pharmaceuticals ltd (455) Snapshot

Open
$0.41
Previous Close
$0.41
Day High
$0.41
Day Low
$0.39
52 Week High
03/11/14 - $0.50
52 Week Low
02/4/14 - $0.32
Market Cap
748.0M
Average Volume 10 Days
743.8K
EPS TTM
$0.01
Shares Outstanding
1.9B
EX-Date
09/8/14
P/E TM
34.1x
Dividend
$0.0024
Dividend Yield
0.60%
Current Stock Chart for TIANDA PHARMACEUTICALS LTD (455)

Related News

No related news articles were found.

tianda pharmaceuticals ltd (455) Related Businessweek News

No Related Businessweek News Found

tianda pharmaceuticals ltd (455) Details

Tianda Pharmaceuticals Limited, an investment holding company, is engaged in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products. The company’s principal product consists of Cerebroprotein Hydrolysate Injection for craniocerebral trauma; to improve sequelae of cerebrovascular and improve deficiency of brain function; and that is conducive to those patients who lack protein or with neurasthenia. It offers cardio-cerebrovascular, pediatric, cold and respiratory system, anti-infective, and detoxification drugs, as well as complementary health care products, such as bone health, heart health, immune booster, nutritional oil, vitamin and mineral, women’s nutrition, well being, and personal care products. It operates in the People’s Republic of China, Hong Kong, and Australia. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. Tianda Pharmaceuticals Limited is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

485 Employees
Last Reported Date: 07/29/14

tianda pharmaceuticals ltd (455) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tianda pharmaceuticals ltd (455) Key Developments

Tianda Pharmaceuticals Limited Provides Earnings Guidance for the Six Months Ending September 30, 2014

The Board of Directors of Tianda Pharmaceuticals Limited informed the shareholders of the company and potential investors, based on preliminary assessment of the group's latest unaudited consolidated management accounts and the information currently available, the group is expected to record consolidated loss for the six months ending 30 September 2014, while consolidated profit was recorded in the corresponding period last year. Due to the suspension of original production line of Meng Sheng Pharmaceutical, its sales and earnings recorded a decline compared with the corresponding period last year. Therefore it is anticipated that the group's consolidated results for the six months ending 30 September 2014 will turn to a loss.

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 28, 2014

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 28, 2014., at 10:00 China Standard Time. Location: Suites 2405-2410, 24th Floor, CITIC Tower. Agenda: To receive and consider the audited consolidated financial statements, the report of the directors and the independent auditor's report of the company for the year ended 31 March 2014; to declare a final dividend for the year ended 31 March 2014; to re-elect Mr. Lui Man Sang as an executive Director; to re-elect Mr. Chiu Sung Hong as an independent non-executive Director; to re-elect Mr. Lam Yat Fai as an independent non-executive Director; to authorize the Board of Directors to fix the Directors' remuneration for the year ending 31 March 2015; to re-appoint Deloitte Touche Tohmatsu as auditor and to authorize the Board of Directors to fix the remuneration of auditor; to grant a general mandate to the Directors to repurchase shares of the company; to grant a general mandate to the Directors to allot and issue new shares of the company; and to extend the general mandate granted to allot and issue new shares by adding the shares repurchased by the company.

Tianda Pharmaceuticals Limited Announces Audited Consolidated Earnings Results for the Year Ended March 31, 2014

Tianda Pharmaceuticals Limited announced audited consolidated earnings results for the year ended March 31, 2014. For the year, the company's revenue was HKD 247.17 million compared with HKD 180.2 million a year ago. Profit before tax was HKD 64.4 million compared with HKD 62.9 million a year ago. Profit for the year from continuing operations was HKD 48.95 million compared with HKD 50.8 million a year ago. Profit for the year was HKD 48.95 million compared with HKD 67.7 million a year ago. Profit for the year attributable to the owners of the company from continuing operations was HKD 22.0 million or 1.18 HKD cents per basic share compared with HKD 24.4 million or 1.30 HKD cents per basic share a year ago. Profit for the year attributable to the owners of the company was HKD 22.0 million or 1.18 HKD cents per basic share compared with HKD 37.7 million or 2.02 HKD cents per basic share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
455:HK $0.40 HKD -0.005

455 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 455.
View Industry Companies
 

Industry Analysis

455

Industry Average

Valuation 455 Industry Range
Price/Earnings 34.4x
Price/Sales 3.1x
Price/Book 1.0x
Price/Cash Flow 34.4x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANDA PHARMACEUTICALS LTD, please visit www.tiandapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.